NEW YORK & PARIS--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Cellectis (Paris:ALCLS) today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis’ CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient’s own T-cells to target tumor cells).
Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration | Pfizer Pharmaceutical News and Media | Pfizer: the world's largest research-based pharmaceutical company
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.